Mikhail Kosiborod, MD
Cardiovascular Disease · Kansas City, MONPI 1588613657
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $845,965 of the $1,149,444 with a category attached, or 73.6%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2019 at $376,727 and has fallen 99.9% since, to $300 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $1999.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$248K
- Novo Nordisk AS$230K
- Astrazeneca UK Limited$101K
- Amgen$91K
- AstraZeneca$88K
- Boehringer Ingelheim International GmbH$80K
- plus $312K from 24 others
Across 698 payments — averaging $38,181 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$23.2M
- Boehringer Ingelheim$2.1M
- Bayer$798K
- Novo Nordisk AS$231K
- Pfizer$204K
- Amgen$76K
- plus $27K from 3 others
What the payments were for
- Consulting fees$845,96574%
- Speaking & faculty fees$57,5075%
- Travel & lodging$233,10220%
- Food & beverage$12,8511%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $248,409 |
| Novo Nordisk AS | 61 | $229,757 |
| Astrazeneca UK Limited | 77 | $100,852 |
| Amgen | 47 | $90,653 |
| AstraZeneca | 59 | $87,837 |
| Boehringer Ingelheim International GmbH | 40 | $80,078 |
| Eli Lilly | 48 | $60,191 |
| Sanofi-aventis U.S. LLC | 15 | $51,345 |
| Bayer | 48 | $49,609 |
| Boehringer Ingelheim | 21 | $40,814 |
| Vifor (international) Ltd. | 4 | $20,289 |
| Janssen Scientific Affairs, LLC | 10 | $18,746 |
| Merck | 8 | $15,748 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $11,486 |
| Sanofi US Services Inc. | 2 | $7,257 |
| Astrazeneca AB | 8 | $6,506 |
| Corcept Therapeutics | 6 | $6,182 |
| Amarin Pharma, Inc. | 8 | $5,482 |
| Pfizer | 4 | $3,600 |
| Esperion Therapeutics, Inc. | 6 | $2,884 |
| F. Hoffmann-la Roche AG | 2 | $2,573 |
| Lilly USA, LLC | 1 | $2,400 |
| Boehringer Ingelheim India Pvt. Ltd. | 1 | $1,775 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,500 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,230 |
| Regeneron | 2 | $1,007 |
| Dexcom, Inc. | 1 | $650 |
| Novartis | 2 | $231 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Gilead | 2 | $167 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$184,244
- FARXIGA$97,995
- Repatha$73,054
- JARDIANCE$47,701
- NO PRODUCT DISCUSSED$44,528
- Kerendia$36,365
- INVOKANA$14,850
- Veltassa$13,139
- Non-Covered$12,220
- SOTAGLIFLOZIN$7,257
- PRALUENT$6,708
- Korlym$6,054
- LOKELMA$5,656
- Vascepa$5,165
- Ozempic$4,500
- BRILINTA$3,300
- ONGLYZA$2,750
- NEXLETOL$2,723
- NEXLIZET$2,723
- MOUNJARO$2,400
How this compares
$1,149,444 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 427 | $703,921 |
| JardianceEmpagliflozin | 241 | $327,164 |
| MounjaroTirzepatide | 198 | $257,001 |
| Repatha SureclickEvolocumab | 92 | $112,813 |
| FarxigaDapagliflozin Propanediol | 102 | $94,059 |
| TrulicityDulaglutide | 51 | $65,016 |
| EliquisApixaban | 53 | $55,761 |
| KerendiaFinerenone | 40 | $55,086 |
| Praluent PenAlirocumab | 29 | $38,191 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $9,932 |
| Ezetimibe | 288 | $7,301 |
| Pioglitazone Hcl | 380 | $4,683 |
| Rosuvastatin Calcium | 284 | $4,521 |
| Metformin Hcl ErMetformin Hcl | 134 | $1,770 |
| Atorvastatin Calcium | 170 | $1,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $248,409 | $703,921427 claims |
| Boehringer IngelheimJardiance | $40,814 | $327,164241 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,400 | $322,017249 claims |
| AstraZenecaFarxiga | $87,837 | $94,059102 claims |
| PfizerEliquis | $3,600 | $55,76153 claims |
| BayerKerendia | $49,609 | $55,08640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Kansas City
- John SpertusKansas City$360K
- Kyle LehenbauerKansas City$108K
- Deepa UpadhyayaKansas City$58K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.